Drugs / LY4584180
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07226843 | Apr 2026 → Sep 2028 expected | diffuse large B-cell lymphoma, follicular lymphoma | Eli Lilly and Company | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY4584180 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07226843 ↗ |
| Route | Oral | “administered orally” NCT07226843 ↗ |